- Home
- DOV vs BIIB Comparison
DOV vs BIIB Comparison
Compare DOV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOV
- BIIB
- Stock Information
- Founded
- DOV 1947
- BIIB 1978
- Country
- DOV United States
- BIIB United States
- Employees
- DOV N/A
- BIIB N/A
- Industry
- DOV Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DOV Industrials
- BIIB Health Care
- Exchange
- DOV Nasdaq
- BIIB Nasdaq
- Market Cap
- DOV 27.6B
- BIIB 25.1B
- IPO Year
- DOV N/A
- BIIB 1991
- Fundamental
- Price
- DOV $201.32
- BIIB $157.78
- Analyst Decision
- DOV Buy
- BIIB Buy
- Analyst Count
- DOV 11
- BIIB 25
- Target Price
- DOV $209.09
- BIIB $258.57
- AVG Volume (30 Days)
- DOV 617.3K
- BIIB 1.6M
- Earning Date
- DOV 01-30-2025
- BIIB 10-30-2024
- Dividend Yield
- DOV 1.02%
- BIIB N/A
- EPS Growth
- DOV 53.59
- BIIB 10.05
- EPS
- DOV 11.19
- BIIB 11.06
- Revenue
- DOV $8,474,513,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- DOV N/A
- BIIB N/A
- Revenue Next Year
- DOV $5.16
- BIIB N/A
- P/E Ratio
- DOV $18.30
- BIIB $14.26
- Revenue Growth
- DOV 7.02
- BIIB N/A
- 52 Week Low
- DOV $143.31
- BIIB $153.62
- 52 Week High
- DOV $208.26
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- DOV 52.00
- BIIB 33.43
- Support Level
- DOV $202.05
- BIIB $158.44
- Resistance Level
- DOV $208.26
- BIIB $162.62
- Average True Range (ATR)
- DOV 2.44
- BIIB 3.19
- MACD
- DOV -0.67
- BIIB 0.90
- Stochastic Oscillator
- DOV 40.33
- BIIB 35.65
About DOV Dover Corporation
Dover Corp is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.